IASO Biotherapeutics Receives FDA Approval for CT103A IND Application
China-based IASO Biotherapeutics has announced approval from the US FDA for an Investigational New Drug...
IASO Biotherapeutics
IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform
China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...
IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD
China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...
IASO Biotherapeutics Licenses CD19 Binder to Cabaletta Bio for Autoimmune Diseases
China-based IASO Biotherapeutics has announced a licensing agreement with US firm Cabaletta Bio Inc. (NASDAQ:...
IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China
China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational...